The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis

SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) has shown variable response rates between 9% and 39%. Therefore, better criteria are needed that help doctors to identify patients who will show a favorable outcome to PRRT, and which patients may not. The so...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruhwedel, Tristan, Rogasch, Julian M. M., Huang, Kai, Jann, Henning, Schatka, Imke, Furth, Christian, Amthauer, Holger, Wetz, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915791/
https://www.ncbi.nlm.nih.gov/pubmed/33562643
http://dx.doi.org/10.3390/cancers13040635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915791/
https://www.ncbi.nlm.nih.gov/pubmed/33562643
http://dx.doi.org/10.3390/cancers13040635

Ejemplares similares